Valproate – reproductive risks

AI Summary

This summary outlines the UK Medicines and Healthcare products Regulatory Agency (MHRA) guidance for valproate-containing medicines, such as Epilim and Depakote, used to treat epilepsy and bipolar disorder. The guidance addresses critical safety issues: a 11% risk of birth defects and a 30-40% risk of permanent developmental disorders in children exposed during pregnancy. Emerging data also suggests potential neurodevelopmental risks to children fathered by men taking the medication, as well as risks of male infertility. Under the established regulatory framework, including the Pregnancy Prevention Programme and National Patient Safety Alerts updated between 2023 and 2025, strict prescribing conditions apply. For patients under 55, valproate should only be initiated if two specialists agree that alternative treatments are unsuitable. Required actions include the mandatory completion of Risk Acknowledgement Forms for both male and female patients to ensure they understand reproductive risks. Patients must use effective contraception, and healthcare providers are required to supply specific educational materials and patient cards. Furthermore, pharmacists must dispense the medication in its original packaging to ensure all safety warnings are visible. Patients are advised never to stop treatment without specialist consultation due to the risk of severe relapse.